If I have a nickel for every time a Head of BD asked me, "Should we do AACR or ASCO this year?" I’d have retired from the conference circuit by 2020. The truth is, there is no generic "right" answer. If you are operating in the oncology space, your choice in 2026 isn't just about attendance—it's about where your capital formation strategy meets your clinical pipeline.
After a decade of staffing booths, surviving the JPM Week chaos in San Francisco, and managing partnering calendars, I’ve learned one thing: Conference ROI is often murdered by the "fear of missing out." You need to stop asking which meeting is bigger and start asking which meeting matches your current inflection point.
The Fundamental Divide: Science vs. Scale
Before we dive into the weeds, let’s look at the functional difference. The AACR oncology research meeting is the cathedral of preclinical and translational science. This is where you go if your mechanism of action is novel, your multiomics data is the lead story, and you are hunting for collaborators or early-stage venture capital.
ASCO, by contrast, is the clinical beast. It is where data reads for Phase II and III trials turn into commercial reality. If you are looking for partnerships with Big Pharma or preparing for an IPO, ASCO is the stage. But, be warned: at ASCO, unless you have a major data readout, you are a needle in a haystack the size of Chicago’s McCormick Place—a venue that, frankly, is a logistical nightmare https://bioinformant.com/top-us-life-sciences-biotech-conferences/ for ad-hoc meeting flow.
Opportunity Cost and the "Events that Look Good on Paper" Trap
I see companies burning their entire Q2 budget on a flashy booth at a massive conference because their marketing firm promised "brand visibility." Let’s be clear: unless you are a tier-one player, a badge scan is rarely a lead. It’s just noise.
In 2026, you need to calculate the opportunity cost. If you are a lean biotech, spending $80k on a 20x20 island booth at ASCO—where the floor traffic is essentially a stampede—is often a waste of time. Your BD team spends the whole week dodging booth traffic rather than having high-quality, 1:1 sessions in a quiet hotel lobby or a nearby cafe.
Speaking of data and digital footprints, have you noticed how many conference websites are now cluttered with tracking tech? When you’re researching these events, you’re constantly hit with CookieYes consent banners. Behind the scenes, those sites are scrubbing your browser data using Cloudflare Bot Management—tracking your __cf_bm, __cfruid, _cfuvid, and cf_clearance cookies to ensure you aren't a scraper. It’s ironic: the more these organizers track you, the less they actually know about your specific BD needs.
Partnering Volume and the Role of partneringONE
If you are serious about BD, you aren't "networking"—you are *partnering*. Whether it’s a Demy-Colton salon or an Informa Connect summit, the format matters. At large-scale oncology events, the efficiency of your meeting calendar is dictated by the software.
The partneringONE platform is the gold standard, but it only works if you approach it with a "sniper" mentality.
- The Pre-Meeting Strategy: Don't wait until you arrive to fill your calendar. The most valuable meetings are booked three weeks out. The Venue Strategy: If you are using an external partnering system, pick a meeting spot that isn't the conference center itself. If you're in San Diego for AACR, find a quiet lobby in the Gaslamp Quarter. Don't waste 20 minutes walking through a crowd to find a "designated meeting zone" that is actually just a loud, open-air table. Function-Specific Focus: AACR is better for early-stage platform partnering. ASCO is better for clinical co-development deals. If you force a platform-only deck on a clinical-stage partner at ASCO, you’ve wasted both your times.
Comparison: AACR vs. ASCO for 2026
Feature AACR (Research Meeting) ASCO (Clinical Meeting) Primary Audience Scientists, Translational Leads, VCs Physicians, Pharma BD, Investors Best For Genomics, Multiomics, MOA validation Pivotal data, Commercial partnerships Meeting Vibe Collaborative, data-heavy, intense High-stakes, frenetic, noisy BD Utility High (Preclinical/Early Phase) High (Clinical/Commercial)Genomics and Multiomics: The Tech-Forward Shift
The 2026 oncology landscape is heavily skewed toward multiomics and precision medicine. If your company is doing single-cell sequencing or spatial biology, AACR is your natural habitat. The investor crowd at AACR is increasingly looking for the "next big thing" in precision oncology. At ASCO, the conversation is shifting toward "how do we pay for this" and "what is the clinical benefit."
My advice? Use AACR to build the scientific narrative with investors. Use the time leading up to JPM Week to solidify the valuation based on the data you presented at AACR. If you try to pitch raw multiomics data at ASCO, you will get lost in the noise of clinical trial success stories.
Final Strategy: The 2026 Playbook
So here's the deal: here is how you decide:
Assess your Pipeline: If your lead asset is preclinical or early Phase I, lean into the AACR oncology research meeting. It’s where the scientists who influence the investors spend their time. Assess your Funding Stage: If you are prepping for a Series B or C, or looking for a co-development deal, ASCO is the venue to see and be seen. Just remember to secure a room in a nearby hotel for meetings, or you will lose your mind trying to find a corner to sit in. Vet the Attendees: Don't just trust the "Total Attendance" number. Ask for the breakdown. If the list is heavy on academic post-docs and light on corporate BD, adjust your goals accordingly. Ignore the Buzz: Stop chasing "networking events" held at loud bars. The best deals happen in 20-minute, scheduled slots with prepared data, not over a watered-down gin and tonic at an after-party.And one final pro-tip: If you're checking your own site metrics or researching conference providers, don't ignore the technical overhead. If you're seeing a flood of cf_clearance cookies being dropped on your own site from a partner, it means the bot traffic is real. Use that information to decide if you're actually reaching humans or just feeding an algorithm. In the world of 2026 biotech BD, knowing the difference is exactly what separates the winners from the "badge-scanners."